{"id":"placebo-and-prednisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Osteoporosis (with chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone is a systemic corticosteroid that works by binding to glucocorticoid receptors and suppressing T-cell activation, cytokine production, and inflammatory responses. In this phase 3 trial, it serves as an active comparator control arm against which an investigational Janssen therapy is being evaluated. The placebo component indicates this is a blinded trial design.","oneSentence":"This is a comparator arm combining placebo with prednisone, a corticosteroid that suppresses immune function and reduces inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:35.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active comparator arm in phase 3 clinical trial (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT06934915","phase":"EARLY_PHASE1","title":"Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Christopher John McDougle, M.D.","startDate":"2026-11","conditions":"Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder","enrollment":32},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT04497844","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-23","conditions":"Metastatic Castration-sensitive Prostate Cancer","enrollment":696},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT03748641","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-25","conditions":"Castration-Resistant Prostatic Cancer","enrollment":765},{"nctId":"NCT06585774","phase":"PHASE3","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-01-21","conditions":"Chronic Graft-versus-host-disease","enrollment":240},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT05379634","phase":"PHASE2","title":"A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-05","conditions":"Myositis","enrollment":36},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT05767034","phase":"PHASE3","title":"Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-22","conditions":"Polymyalgia Rheumatica","enrollment":381},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT06624670","phase":"PHASE3","title":"A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-02-04","conditions":"Pyoderma Gangrenosum","enrollment":90},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT05674994","phase":"PHASE3","title":"Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2023-10-26","conditions":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":110},{"nctId":"NCT04930094","phase":"PHASE3","title":"Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Giant Cell Arteritis (GCA)","enrollment":355},{"nctId":"NCT03153527","phase":"PHASE4","title":"Taper Or Abrupt Steroid Stop: TOASSTtrial","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-05-31","conditions":"Inflammatory Disorder, Autoimmune","enrollment":530},{"nctId":"NCT03725202","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-01-24","conditions":"Giant Cell Arteritis (GCA)","enrollment":429},{"nctId":"NCT06356129","phase":"PHASE3","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-06-19","conditions":"Large B-cell Lymphoma","enrollment":850},{"nctId":"NCT07286214","phase":"PHASE4","title":"Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-04-15","conditions":"Polymyalgia Rheumatica","enrollment":300},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Lupus Nephritis","enrollment":271},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT04844814","phase":"PHASE2","title":"Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation","status":"SUSPENDED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-02","conditions":"Gout, Chronic Kidney Disease, Renal Transplantation","enrollment":204},{"nctId":"NCT07223580","phase":"PHASE4","title":"A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-23","conditions":"Ureteroscopy, Post Operative Pain","enrollment":90},{"nctId":"NCT07380152","phase":"PHASE1","title":"Corticosteroid Therapy in Pulmonary Sequelae of Covid-19","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2021-08-10","conditions":"COVID-19 Pulmonary Complications","enrollment":100},{"nctId":"NCT07258771","phase":"PHASE4","title":"Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2026-01-16","conditions":"Ulcerative Colitis Acute","enrollment":110},{"nctId":"NCT07060638","phase":"PHASE2","title":"Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial","status":"RECRUITING","sponsor":"Samer Gawrieh","startDate":"2026-01-27","conditions":"Alcohol-associated Hepatitis","enrollment":216},{"nctId":"NCT03732820","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-31","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":895},{"nctId":"NCT04474847","phase":"PHASE3","title":"Abatacept for the Treatment of Giant Cell Arteritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-03-29","conditions":"Giant Cell Arteritis","enrollment":78},{"nctId":"NCT04493853","phase":"PHASE3","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-13","conditions":"Hormone-Sensitive Prostate Cancer","enrollment":1012},{"nctId":"NCT04951986","phase":"PHASE3","title":"Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cape Town","startDate":"2021-08-11","conditions":"Disseminated Tuberculosis, HIV","enrollment":732},{"nctId":"NCT04529772","phase":"PHASE3","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2020-10-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":611},{"nctId":"NCT05201469","phase":"PHASE2","title":"VIBRANT: VIB4920 for Active Lupus Nephritis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-05-16","conditions":"Lupus Nephritis","enrollment":74},{"nctId":"NCT06625671","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-10-04","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":148},{"nctId":"NCT05643638","phase":"PHASE2","title":"A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD","status":"RECRUITING","sponsor":"Cynata Therapeutics Limited","startDate":"2024-03-04","conditions":"Graft Versus Host Disease, Acute","enrollment":60},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT02997605","phase":"PHASE4","title":"Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-01-31","conditions":"RheumatoId Arthritis","enrollment":102},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT01407484","phase":"NA","title":"Male Infertility Related With Post Infection Inflammatory Syndrome","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-03-02","conditions":"Male Infertility, Leukopenia, Postinfection Inflammation","enrollment":200},{"nctId":"NCT06453694","phase":"PHASE2","title":"Efgartigimod for the Treatment of Acute Optic Neuritis","status":"RECRUITING","sponsor":"Anastasia Vishnevetsky, MD, MPH","startDate":"2025-08-12","conditions":"Optic Neuritis","enrollment":20},{"nctId":"NCT06841705","phase":"PHASE2","title":"Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial","status":"RECRUITING","sponsor":"Shilpa Grover, MD, MPH","startDate":"2025-07-15","conditions":"Immune Checkpoint Inhibitor-Related Colitis","enrollment":80},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":473},{"nctId":"NCT05267600","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","status":"COMPLETED","sponsor":"argenx","startDate":"2022-06-09","conditions":"Bullous Pemphigoid","enrollment":98},{"nctId":"NCT03584516","phase":"PHASE2, PHASE3","title":"GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-01-17","conditions":"Chronic Graft-versus-host Disease","enrollment":155},{"nctId":"NCT06143891","phase":"PHASE3","title":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-01-23","conditions":"Chronic Graft Versus Host Disease","enrollment":260},{"nctId":"NCT06729593","phase":"PHASE3","title":"Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":87},{"nctId":"NCT06729606","phase":"PHASE3","title":"Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":471},{"nctId":"NCT06119529","phase":"PHASE1","title":"A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2023-11-01","conditions":"Healthy, Atopic Dermatitis","enrollment":18},{"nctId":"NCT03545464","phase":"PHASE3","title":"COrticosteroids in acUte uRticAria in emerGency dEpartment","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-09-21","conditions":"Urticaria, Angiœdema","enrollment":137},{"nctId":"NCT01570764","phase":"PHASE3","title":"Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-01-14","conditions":"Systemic Sclerosis, Scleroderma, Interstitial Lung Disease","enrollment":40},{"nctId":"NCT02330952","phase":"PHASE4","title":"Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02-10","conditions":"Pulmonary Disease, Chronic Obstructive (MeSH)","enrollment":189},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT03834506","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":1030},{"nctId":"NCT05288166","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-04-14","conditions":"Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms","enrollment":925},{"nctId":"NCT04354649","phase":"PHASE2","title":"Immune-Mediated Pathophysiology And Clinical Triage Program","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2021-09-16","conditions":"Arthritis, Arthralgia","enrollment":46},{"nctId":"NCT04100018","phase":"PHASE3","title":"A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-02-06","conditions":"Prostate Cancer","enrollment":1030},{"nctId":"NCT03072238","phase":"PHASE3","title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-06-30","conditions":"Metastatic Prostate Cancer","enrollment":1101},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT06981845","phase":"NA","title":"Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-06-01","conditions":"In-stent Restenosis Lesion, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))","enrollment":52},{"nctId":"NCT00004448","phase":"PHASE2","title":"Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1997-11","conditions":"IgA Glomerulonephritis","enrollment":96},{"nctId":"NCT02981979","phase":"NA","title":"Takayasu Arteritis Clinical Trial in China","status":"COMPLETED","sponsor":"Jiang lindi","startDate":"2016-12-22","conditions":"Takayasu Arteritis","enrollment":116},{"nctId":"NCT03706365","phase":"PHASE2, PHASE3","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2018-11-26","conditions":"Prostate Cancer","enrollment":393},{"nctId":"NCT02496585","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-07-08","conditions":"Lung Cancer, Lung Metastases","enrollment":34},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":"Prostatic Neoplasms","enrollment":806},{"nctId":"NCT06833814","phase":"PHASE4","title":"DOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations","status":"NOT_YET_RECRUITING","sponsor":"Andréanne Côté","startDate":"2025-02-17","conditions":"Asthma Exacerbations","enrollment":36},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT04072822","phase":"PHASE2","title":"Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-07-10","conditions":"Alcoholic Hepatitis","enrollment":147},{"nctId":"NCT05349006","phase":"PHASE3","title":"Azathioprine in MOGAD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-12-12","conditions":"Central Nervous System Inflammation, MOG-IgG Associated Disease","enrollment":126},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT01715285","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-02-12","conditions":"Prostate Neoplasms","enrollment":1209},{"nctId":"NCT04691804","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-18","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":496},{"nctId":"NCT02631603","phase":"PHASE2","title":"Stop Exogenous Allergic Alveolitis (EAA) in Childhood","status":"TERMINATED","sponsor":"Matthias Griese","startDate":"2015-04","conditions":"Hypersensitivity Pneumonitis, Exogenous Allergic Alveolitis","enrollment":4},{"nctId":"NCT00650078","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-03","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT04231448","phase":"PHASE3","title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2020-05-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":423},{"nctId":"NCT05542355","phase":"PHASE1","title":"EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease","status":"TERMINATED","sponsor":"Exeliom Biosciences","startDate":"2023-03-20","conditions":"Crohn Disease","enrollment":8},{"nctId":"NCT04598451","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)","status":"COMPLETED","sponsor":"argenx","startDate":"2020-12-01","conditions":"Pemphigus Vulgaris, Pemphigus Foliaceus","enrollment":222},{"nctId":"NCT01393639","phase":"PHASE2","title":"Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-27","conditions":"Rheumatoid Arthritis","enrollment":323},{"nctId":"NCT02550652","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-13","conditions":"Lupus Nephritis","enrollment":126},{"nctId":"NCT00092989","phase":"PHASE3","title":"Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-07","conditions":"Asthma","enrollment":650},{"nctId":"NCT02108860","phase":"PHASE3","title":"Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2015-04-25","conditions":"Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis","enrollment":65},{"nctId":"NCT04907227","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-09-23","conditions":"Prostatic Neoplasms","enrollment":81},{"nctId":"NCT04232449","phase":"PHASE3","title":"Oral Corticosteroids for Post-infectious Cough in Adults","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-11-06","conditions":"Post-infectious Cough","enrollment":32},{"nctId":"NCT04629144","phase":"PHASE2","title":"Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10-20","conditions":"Vasculitis, Cryoglobulinemia","enrollment":48},{"nctId":"NCT03994731","phase":"PHASE4","title":"Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-13","conditions":"Gout","enrollment":152},{"nctId":"NCT05772871","phase":"PHASE4","title":"The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"Jianhua Zhou","startDate":"2023-04-26","conditions":"Nephrotic Syndrome in Children","enrollment":402},{"nctId":"NCT04809623","phase":"PHASE1","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-01","conditions":"Cutaneous Lupus Erythematosus","enrollment":3},{"nctId":"NCT06251232","phase":"PHASE2","title":"Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2024-05-01","conditions":"Hepatotoxicity, Idiosyncratic Drug Effect, Prednisone","enrollment":60},{"nctId":"NCT04654988","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2022-12-01","conditions":"Myocarditis, Heart Failure, Endomyocardial Biopsy","enrollment":100},{"nctId":"NCT06266221","phase":"PHASE3","title":"Severe Erythema Multiforme - CORTICO","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-05-01","conditions":"Erythema Multiforme","enrollment":96},{"nctId":"NCT03752307","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2019-02-15","conditions":"Multiple Sclerosis","enrollment":2},{"nctId":"NCT05000658","phase":"PHASE3","title":"Efficacy of Soluble Dexamethasone in Refractory Sciatica","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2021-12-16","conditions":"Sciatica","enrollment":109},{"nctId":"NCT03371667","phase":"PHASE3","title":"To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-08-16","conditions":"Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute","enrollment":102},{"nctId":"NCT00938587","phase":"PHASE2","title":"A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10-07","conditions":"Rheumatoid Arthritis","enrollment":86},{"nctId":"NCT06145126","phase":"NA","title":"Effects of Glucocortioids in Human Skeletal Muscle, Adipose Tissue and Skin","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2023-12","conditions":"Glucocorticoids Toxicity, Iatrogenic Effect","enrollment":12},{"nctId":"NCT01972217","phase":"PHASE2","title":"Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":158},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":233,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo and prednisone","genericName":"Placebo and prednisone","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a comparator arm combining placebo with prednisone, a corticosteroid that suppresses immune function and reduces inflammation. Used for Active comparator arm in phase 3 clinical trial (specific indication unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}